Our vision: Life Science in Sweden will take the lead to generate world-class health and sustainable growth through innovation and collaboration.
Our mission: SWElife accelerates innovation and collaboration in Life Science – from ideas to societal benefits.
The Swedish Innovation Programme for Life Science against widespread diseases (folksjukdomar) stimulates a new kind of generic models for innovation.
Innovation is valuable in all stages, from idea generation to development and implementation in the health care system. However, Life Science innovation can no longer be performed by individual stakeholders in isolation but requires knowledge and competence from various stakeholders.
SWElife addresses the entire value chain from prevention and diagnosis to treatment through stimulation of interdisciplinary, cross sectional collaborations that will accelerate knowledge and competence sharing throughout the innovation process from idea to patient and society benefit. Hence, all stakeholders aiming to develop new ways to prevent, diagnose, monitor, manage or treat patients with non-communicable diseases benefit from the programme.
Actors in SWElife include the Life Science industry in Sweden (biotech, medtech, pharmaceutical and related industries), the health care system, academic research institutions and patients in collaboration with other stakeholders in the value chain, including innovation systems, incubators, biobanks, investment entities and venture capitalists.
Our long-term goals
- National use of expertise and resources
- Evidence- and value-based healthcare and personalised medicine in practice
- Swedish healthcare has introduced and established more value-creating innovations
- Life Science in Sweden is internationally competitive
- Increasing research and development in Life Science in Sweden.